English planetary scientist Colin Pillinger dies aged 70

English planetary scientist Colin Pillinger, best known for his 2003 attempt to land a spacecraft on Mars, has died aged 70, his family have said.

Prof Pillinger was at his home in Cambridge when he suffered a brain haemorrhage and fell into a deep coma.

His family said he later died at Addenbrooke's Hospital, England, without regaining consciousness.

His death was "devastating and unbelievably sad", they said in a statement.

'Unfinished business'
The space scientist built a probe to search for Martian life, naming it Beagle 2 after Charles Darwin's HMS Beagle.

It was the first time an individual researcher had sent their own vessel into space.

The spacecraft vanished without trace but Prof Pillinger carried on pushing space agencies to complete what he called "unfinished business on Mars".

Fans took to Twitter to pay tribute to the scientist, with author Keith Mansfield calling him a "great advocate" for space and Mars.

Phil Ford, a writer on Dr Who, said: "Very sad to see Prof Colin Pillinger has died. A proper British boffin who will be fondly remembered for the Beagle Mars mission."

At the age of 62 Prof Pillinger was diagnosed with multiple sclerosis, which left him finding it difficult to walk.

He said the illness would not diminish his efforts to land a British craft on Mars.

A professor in interplanetary science at the Open University, he headed the university's Department of Physical Sciences until 2005.

He was awarded a CBE in 2003 and had asteroid 15614 named after him a year later, 2004.

"A piece of Professor Pillinger now moves between Mars and Jupiter," a Nasa scientist said at the time.

Prof Pillinger was married to Judith with whom he had two children, Shusanah and Nicolas.

Aberdeen Scientists Find Link Between Light Deficiency and Multiple Sclerosis

Aberdeen scientists have found that artificial sunlight can have a “striking effect” in helping treat sufferers of diseases such as multiple sclerosis.

Researchers from Aberdeen University studied patients in the north of Scotland – which has the highest rate of MS in the UK - who were being treated during winter with artificial UV (ultraviolet)-B light therapy for skin diseases caused by their immune systems acting inappropriately.

The research - published in the Journal of Allergy and Clinical Immunology – shows how UV-B light boosts vitamin D, as well as cells in our body that are responsible for regulating or balancing the immune system. Vitamin D is made in our bodies by UV-B light from the sun.

Some studies have suggested a link between vitamin D deficiency and autoimmune diseases such as MS.

This possible link might also explain the increasing prevalence of autoimmune disease among those living far from the equator, where there are lower levels of winter sun.

Autoimmune diseases - like MS and type 1 diabetes - are diseases where the immune system mistakenly attacks the body’s own tissues or harmless substances that enter the body.

Dr Anthony Ormerod, clinical reader in dermatology at the university, said: “Our study shows that UV-B light, which mimics sunshine, can have a striking effect on the immune system of patients.

“We found that UV-B light boosted the production of vitamin D, and of regulatory T cells, which play an important role keeping our immune systems in check.

“Our findings have important implications for future interventions including the recommendations for healthy lifestyle and a possible role for phototherapy and/or vitamin D supplementation in the prevention or treatment of autoimmune and inflammatory diseases.

“While too much exposure to sunlight is harmful and increases skin cancer risk, these results suggest that subjects in our study would have some benefits from small amounts equivalent to summer exposure in the winter but more work needs to determine the role of sunlight and the role of supplementing the diet with vitamin D.”

Dr Helen Macdonald, senior lecturer in nutrition and translational musculoskeletal research at the university and chair of the National Osteoporosis Society Nutrition and Lifestyle forum, said: “There are risks associated with high levels of both therapies, so it is important that we get the balance right.

“We would also want to stress that we are not advocating sun bed use since this is not the same type of radiation produced by sun beds which already have well-documented health risks.

“The average dose of UV light that the volunteers received was the equivalent to sunlight exposure in Aberdeen over spring and summer and further work is required to determine if lower doses are effective.”

Professor Mark Vickers, chair in applied medicine at the university, added: “Ours is the first study to demonstrate in patients a cause and effect between UV light, vitamin D and systemic immune function in people.”